Kornimate/medical-research-clean huggingface dataset:
emotional processes in vr exposure treatment for flight phobia

Conditions: Fear of Flying

Summary: this study will assess emotional processes and their relation to treatment outcomes during virtual reality exposure therapy for flight phobia. the researchers hypothesize treatment outcomes will be associated with positive changes in emotional constructs

emotional constructs and emotion regulation capacities play a central role in the severity of anxiety disorders and are directly related to treatment outcomes in different anxiety disorders. in this study we will examine the relation between positive and negative affect, emotion regulation, emotional instability, emotional differentiation, experiential avoidance and therapy outcomes in participants undergoing virtual reality exposure therapy for flight phobia. we assume that treatment outcomes will be positively related to changes in the regulation, management and experience of emotions.

Eligibility criteria:
inclusion criteria: * diagnosis of flight phobia based on a structured interview * possession of a smartphone with an active data plan exclusion criteria: * cardiovascular disease * neurological disorders and history of epilepsy * psychosis * major depression * suicidal behavior * substance abuse.
pragmatic, randomized evaluation of statin active choice to reach improved outcomes based on evidence

Conditions: Cardiovascular Diseases

Summary: in this study, the investigators will conduct a pragmatic, cluster-randomized, controlled trial to evaluate an active choice intervention with and without social comparison feedback to increase physician statin prescribing rates for eligible patients.

cardiovascular disease (cvd) is the leading cause of morbidity and mortality in the united states. strong evidence indicates that statin medications can reduce the risk of cvd and for those with cvd statins have been shown to reduce mortality. despite this evidence, statins are under-prescribed. in this study, the investigators will test the effectiveness of nudges targeted to physicians using active choice and social comparisons feedback to increasing the rate at which statin medications are prescribed to patients eligible based on national practice guidelines.

Eligibility criteria:
inclusion criteria: * patient has a primary care physician at university of pennsylvania health system * patient meets 2013 aha/acc guidelines for statin therapy but no record of a statin prescription in the electronic health record exclusion criteria: * patient has an allergy or adverse reaction to statins documented in the electronic health record * patient has glomerular filtration rate less than 30 ml/min * physicians (and their respective patients) will be excluded if they have less than 10 patients among their entire panel that are eligible for a statin
aromatherapy inhalation in psychiatric nurses

Conditions: Aromatherapy

Summary: in this study will be conducted with a total of 66 psychiatric nurses who meet the inclusion and exclusion criteria and are working at ankara etlik city hospital psychiatry clinic between january 1, 2025 and march 31, 2025.

in this study, aromatherapy inhalation will be applied to psychiatric nurses in the experimental group. aromatherapy inhalation using 2% diluted lavender essential oil will be applied to 33 psychiatric nurses in the experimental group, 30 minutes before starting work, every other day during a week. the "general job stress scale (gjss)" and "therapeutic relationship evaluation scale-nurse form (tres-nf)" inventories will be filled out by 33 psychiatric nurses in the experimental group before and after aromatherapy inhalation, and by 33 psychiatric nurses in the control group simultaneously with the psychiatric nurses in the experimental group.

Eligibility criteria:
inclusion criteria: * written permission was obtained before participating in the study * having worked in the psychiatry departments of the relevant institution for at least 1 year * working in the psychiatry departments of the relevant institution during the study dates * not sensitive to the odor of lavender essential oil exclusion criteria: * previous experience with aromatherapy * sensitivity and allergy to lavender essential oil * willingly leaving the study while the study was ongoing * leaving the job during the study period * general condition changes during the study period (developing allergies, getting sick, taking annual leave, taking leave with a health report) * becoming a service responsible nurse

Keywords: psychiatric nursing inhalation aromatherapy therapeutic relationship work stress
a phase ⅲ study of extended-release carvedilol sulfate for the treatment of hypertension

Conditions: Hypertension

Summary: the aim of present study is to evaluate the efficacy and safety of extended-release carvedilol sulfate versus in patients with mild or moderate primary hypertension


Eligibility criteria:
inclusion criteria: * males or females * aged from 18 to 70 years * had a history of essential hypertension * average sitting diastolic blood pressure≧90mmhg，but≦109mmhg exclusion criteria: * malignant hypertension * average sitting systolic blood pressure≧180mmhg * type 2 diabetes with hemoglobin a1c≥9% * type 1 diabetes * new york heart association class ⅱ-ⅳ congestive heart-failure * unstable angina * second or third degree heart block or history of sick sinus syndrome unless a pacemaker was in place * atrial fibrillation * bradycardia (\<60 bpm, seated) * asthma or other obstructive pulmonary disease * history of myocardial infarction * stroke in the 6 months before screening * known contraindications to β-adrenergic blocker therapy * glutamic-oxaloacetic transaminase and/or glutamic-pyruvic transaminase\>3 times upper limit of normal * crea\>2 times upper limit of normal * pregnancy or lactation

Keywords: hypertension
5 years long term results after standalone cypass-implantation

Conditions: Glaucoma

Summary: this study evaluates the results of all clinically relevant findings of glaucoma diagnostics 5 years after stent-implantation concerning the safety and effectiveness of the cypass stent procedure. the comparison of preoperative and long term postoperative results is the aim of this study to evaluate this young procedure of glaucoma surgery

this is a post market study without interventions.the participants have been treated with cypass-stent implantation between 3 and 7 years ago to control the intraocular pressure . they will be invited for only one follow up visit to determine the present glaucoma status again, to determine the long term safety and effectiveness of the cypass stent procedure and to see whether addition therapy or surgical intervention is necessary.

Eligibility criteria:
inclusion criteria: * patients who have undergone a standalone cypass implantation at least 3 years ago * signed inform consent exclusion criteria: * patients with too much travel distance between study center and home * patients who cannot visit the studycenter due to health problems

Keywords: late effects of surgery
computed tomography (ct) and lung function data collection for computational fluid dynamics (cfd) in chronic obstructive pulmonary disease (copd) patients

Conditions: Chronic Obstructive Pulmonary Disease

Summary: in this study, 20 copd patients will undergo a high-resolution/multi slice ct scan and lung function tests to obtain patient specific geometries of the central and peripheral small airways and patient specific boundary conditions. with computational fluid dynamics (cfd), the investigators will be able to reconstruct the geometry and measure the resistance of the peripheral airways. in a later stage, cfd will be used to simulate the reaction of the airways on various inhalation medications.


Eligibility criteria:
inclusion criteria: 1. patients with documented copd based on the following criteria: * smoking history of at least 10 pack-years. * decreased tiffeneau index (fev1/(f)vc \< 0.70). 2. patients aged ≥ 40 years. 3. patients should present moderate to very severe copd with an fev1 \< 80% of predicted (gold 2, 3 and 4). 4. patients should be treated according to gold guidelines. 5. maintained on stable respiratory medications for 4 weeks prior to visit 1 6. able to perform lung function tests. exclusion criteria: 1. patients below the age of 40. 2. patients who are pregnant or are breast-feeding. 3. a respiratory infection or exacerbation of copd in the four weeks prior to screening. 4. bmi \> 35 kg/m². 5. patients treated with bipap or cpap. 6. known active tuberculosis. 7. a history of asthma, cystic fibrosis, central bronchiectasis, interstitial lung disease or pulmonary thromboembolic disease. 8. a history of thoracotomy with pulmonary resection. 9. active or untreated malignancy.

Keywords: copd
premicron suture for cardiac valve repair

Conditions: Aortic Valve Stenosis

Summary: the study is a voluntary study, initiated by b. braun to collect clinical data for premicron® suture concerning its key indication.


Eligibility criteria:
inclusion criteria: * patients undergoing an elective primary open or minimal invasive surgery for a single or multiple cardiac valve reconstruction or / and replacement. * age ≥18 years * written informed consent exclusion criteria: * patients undergoing an elective primary cardiac valve reconstruction or / and replacement in combination with a coronary arterial bypass graft surgery. * emergency surgery * pregnancy * infective endocarditis * previous cardiac surgical intervention * known immunodeficiency or immunosuppression * participation or planned participation in another cardiovascular study before study follow-up is completed. * inability to give informed consent due to mental condition, mental retardation, or language barrier.

Keywords: elective surgery minimally invasive surgery cardiac valve reconstruction cardiac valve replacement
guided bone regeneration using fixed vs non-fixed resorbable collagen membranes

Conditions: Bone Resorption

Summary: the aim of this clinical trial is to compare the horizontal bone gain when grafting a bone substitute with non fixed resorbable collagen membranes (control group), versus fixed resorbable collagen membranes (test group) in resorbed ridges requiring guided bone regeneration (gbr) to facilitate implant placement at 6 months.

the aim of this clinical trial is to compare the horizontal bone gain when grafting a mixture of xenograft and allograft (50/50) with non fixed resorbable collagen membranes (control group), versus fixed resorbable collagen membranes (test group) in resorbed ridges requiring guided bone regeneration (gbr) to facilitate implant placement at 6 months.

Eligibility criteria:
inclusion criteria: 1. men and women over 18 years old or older 2. patients requiring guided bone regeneration due to insufficient ridge width(≤5mm) to place dental implants, with sufficient vertical ridge height (≥9mm) from vital anatomical structures (the inferior alveolar nerve in the mandible, or the sinus in the maxilla) 3. one or more teeth missing in posterior zone (premolars, and molars) 4. absence of active periodontal disease 5. good level of oral hygiene (plaque index \<25%) 6. absence of systemic diseases that could influence the outcome of the therapy (uncontrolled diabetes, osteoporosis, bisphosphonate medications) 7. non smokers or light smokers (\<10 cigarettes per day) 8. informed consent signed exclusion criteria: 1. patients with sufficient ridge width (\>5 mm) and height (≥9mm) from vital anatomical structure) requiring no gbr to place dental implants 2. patients with severe horizontal and vertical defects requiring other surgical techniques. 3. long-term non-steroidal anti-inflammatory drug therapy (3months). 4. lactating females or currently pregnant women. 5. severe cognitive or psychiatric disorders. 6. unwillingness to return for follow-up examination.
study of combination therapy with ldt plus adefovir versus adefovir alone

Conditions: Hepatitis B

Summary: this study is being conducted to compare the safety and effectiveness of the investigational medication ldt (telbivudine) used in combination with adefovir dipivoxil (a drug currently approved by the food and drug administration \[fda\] for the treatment of hepatitis b virus \[hbv\]) versus adefovir dipivoxil used alone. the results for patients taking the combination therapy will be compared to the results for patients taking adefovir alone.


Eligibility criteria:
inclusion criteria: * documented compensated chronic hepatitis b defined by a clinical history compatible with chronic hepatitis b. * previous or current lamivudine treatment * hbv dna \> 6 log10 copies/ml * evidence of viral breakthrough other protocol-defined inclusion criteria may apply. exclusion criteria: * patient is pregnant or breastfeeding. * patient is co-infected with hepatitis c virus (hcv), hepatitis d virus (hdv), or hiv. * patient has received any anti-hbv treatment for hbv infection other than lamivudine in the 12 months before screening for this study. other protocol-defined exclusion criteria may apply.

Keywords: lamivudine resistance hepatitis b virus
digidiab pilot spain - nursing home and domiciliary nursing care

Conditions: Type 2 Diabetes

Summary: glucotab is a stand-alone software system to support healthcare professionals in the care of patients with diabetes mellitus or newly diagnosed hyperglycaemia who are treated with insulin and/or other glucose-lowering drugs or of patients only requiring glucose monitoring. it provides a therapy algorithm for subcutaneous basal insulin therapy of patients with type 2 diabetes, which will be used in this study.

glucotab: the ce-marked medical device glucotab is a system designed to support healthcare personnel in managing insulin therapy for patients with diabetes. in this study, only the glucotab algorithm supported basalinsulin therapy will be used, which is intended for patients with type 2 diabetes in domiciliary nursing care and nursing homes requiring insulin therapy.

Eligibility criteria:
inclusion criteria: * elderly people, willing to be treated with a basal insulin therapy according to the glucotab system * informed consent obtained after being advised of the nature of the study * male or female aged ≥ 18 years * type 2 diabetes (treated with insulin therapy) * residents of participating nursing homes/domiciliary nursing care in the region of camp de tarragona (spain). exclusion criteria: * type 1 diabetes mellitus * intravenous insulin therapy * hyperglycaemic episodes (ketoacidosis, hyperosmolar state) if they require intravenous insulin therapy * continuous subcutaneous insulin infusion * gestational diabetes or pregnancy * known or suspected allergy to insulin * total parenteral nutrition * any mental condition rendering the patient incapable of giving his/her consent * any disease or condition which according to the investigator would interfere with the trial or the safety of the patient

Keywords: glucotab type 2 diabetes
predictive value of renal venous flow profiles for adverse outcomes in right heart failure

Conditions: Pulmonary Hypertension; Cardiorenal Syndrome; Heart Failure

Summary: predictive value of renal venous flow profiles for adverse outcomes in patients with right heart failure

persistent congestion with deteriorating renal function is an important cause of adverse outcomes in heart failure. the investigators aimed to characterize new doppler ultrasonography approaches to evaluate the continuum of renal congestion. pulmonary hypertension is the most common precursor to right heart failure and thus represents an ideal scenario to study congestion. the second cohort comprises consecutive cardiology inpatients aged ≥18 years with a new or pre-existing diagnosis of heart failure who are referred to the consultant nephrologist with a history of diuretic-resistant fluid overload and impaired renal function. the investigators choose patients with heart failure to broaden the findings to the most common clinical entity of right ventricular failure.

Eligibility criteria:
pulmonary hypertension cohort: exclusion criteria: * ckd stage 5 (kdigo) * pre-existing acute kidney injury (acute kidney injury was defined as an increase in serum creatinine by ≥ 0.3 mg/dl within 48 hours or to ≥ 1.5 times baseline within the prior 7 days, as determined by all available serum creatinine values from hospital and outpatient medical records within the previous 90 days) * non-end stage renal disease patients with extracorporeal or peritoneal ultrafiltration for treatment of diuretic-resistant fluid overload * patients with primary kidney disease (e.g., glomerulonephritis, autosomal dominant polycystic kidney disease, postrenal obstruction) * solid-organ transplant recipients * use of non-steroidal inflammatory drugs within 72 hours before right heart catheterization heart failure cohort: exclusion criteria same as in the discovery cohort except pre-existing acute kidney injury * patients with mechanical assist devices are excluded

Keywords: renal doppler ultrasonography venous congestion
palliative therapy with or without chemotherapy in treating patients with malignant mesothelioma

Conditions: Malignant Mesothelioma

Summary: rationale: palliative therapy may help patients with advanced cancer live more comfortably. it is not yet known if palliative therapy is more effective with or without chemotherapy in treating patients who have malignant mesothelioma. purpose: randomized phase ii trial to compare the effectiveness of palliative therapy with or without different chemotherapy regimens in treating patients who have malignant mesothelioma.

objectives: * determine the feasibility of palliative therapy alone versus palliative therapy with mitomycin, vinblastine, and cisplatin versus palliative therapy with vinorelbine in patients with malignant mesothelioma. * determine the quality of life of patients treated with these regimens. outline: this is a randomized, multicenter study. patients are randomized to one of three treatment arms. * arm i: patients receive palliative therapy alone comprising non-chemotherapeutic therapy (e.g., radiotherapy, painkillers, steroids, relaxants, and special pain relief techniques). * arm ii: patients receive palliative therapy as in arm i and chemotherapy comprising mitomycin iv (courses 1, 2, and 4 only), vinblastine iv, and cisplatin iv over 4 hours on day 1. chemotherapy repeats every 21 days for a total of 4 courses. * arm iii: patients receive palliative therapy as in arm i and chemotherapy comprising vinorelbine iv over 5 minutes once weekly on weeks 1-6 and 9-14. quality of life is assessed at baseline for all patients; at weeks 3, 6, 9, and 12 for arm i; at weeks 4, 7, 10, and 13 for arm ii; at weeks 3, 6, 10, and 13 for arm iii; at weeks 21 and 29, and then every 8 weeks thereafter for all patients. patients are followed every 8 weeks. projected accrual: a total of 60 patients (20 per treatment arm) will be accrued for this study within 1 year.

Eligibility criteria:
disease characteristics: * immunohistochemically or cytologically confirmed malignant mesothelioma * epithelial and other histological types * symptomatic pleural effusion allowed if treated and controlled by drainage, pleurodesis, or pleurectomy * prior surgical resection allowed if stable or progressive disease by 2 ct scan measurements at least 6 weeks apart patient characteristics: age: * not specified performance status: * who 0-2 life expectancy: * not specified hematopoietic: * wbc greater than 3,000/mm3 * neutrophil count greater than 1,500/mm3 * platelet count greater than 100,000/mm3 hepatic: * not specified renal: * not specified other: * considered medically fit to receive chemotherapy * no other disease or prior malignancy that would preclude study * no clinical evidence of infection prior concurrent therapy: biologic therapy: * not specified chemotherapy: * no prior chemotherapy for mesothelioma endocrine therapy: * not specified radiotherapy: * not specified surgery: * see disease characteristics

Keywords: localized malignant mesothelioma advanced malignant mesothelioma recurrent malignant mesothelioma
driving performance after middle of the night administration of 3.5 mg zolpidem tartrate sublingual tablet

Conditions: Insomnia

Summary: a study in healthy volunteers of the next morning driving performance after middle-of-the-night dosing of 3.5 mg zolpidem tartrate sublingual tablet, a sleep aid. the next morning driving performance will be measured by taking a standardized driving test.


Eligibility criteria:
inclusion criteria: * male or female subjects between the ages of 21 and 64 inclusive. for female subjects only: female subjects will be included if they are post-menopausal or sterilized, or if they are of childbearing potential, they are not breastfeeding, their pregnancy test is negative, they have no intention of becoming pregnant during the course of the study, and are using adequate contraceptive drugs or devices. medically acceptable methods of contraception that may be used by the subject and/or her partner are: oral contraceptives, progestin injection or implants, condom with spermicide, diaphragm with spermicide, iud, vaginal spermicidal suppository, surgical sterilization or abstinence. females using oral contraception must have started using the medication at least 4 weeks prior to screening. surgical sterilization must have occurred at least 6 weeks prior to screening. * good health on the basis of pre-study history and physical examination, vital signs and the results of blood chemistry, hematology, and urinalysis * good binocular visual acuity, corrected or uncorrected * possession of valid driver's license for 3 years or more * driving experience at least 3000 km/year * signed informed consent exclusion criteria: * a history of drug addiction or drug or substance abuse, including alcohol abuse, within the past 12 months * has a history of restless legs syndrome, sleep apnea, narcolepsy or other primary sleep disorder * a known hypersensitivity to zolpidem or zopiclone * has undergone oral surgery, tooth extraction or piercing of the lip/tongue within 60 days prior to screening * has used any medication to promote sleep, including herbal medications, within 14 days (or 5 half-lives of the drug, whichever is longer) prior to screening * prescription medications for other health conditions are allowed as long as the subject has been on a stable dose at least 30 days prior to screening * has taken any drugs known to induce hepatic drug metabolism (i.e., rifampin) within 30 days prior to screening * bmi \> 29 kg/m\^2 * current use of medication that affects driving performance * smokes more than 10 cigarettes/day * uses tobacco products during periods of nighttime awakening * consumes more than 6 cups of coffee/day * consumes more than 21 glasses of alcohol/week * has received an investigational drug within 60 days or 5 half-lives (whichever is longer) prior to screening * has any additional condition(s) that in the investigator's opinion would: * affect sleep/wake function * prohibit the subject from completing the study * not be in the best interest of the subject to participate in the study

Keywords: insomnia
a study of two approved drugs in the treatment of postoperative dental pain (0966-181)(completed)

Conditions: Postoperative Pain

Summary: the purpose of this study is to compare the safety and effectiveness of two approved drugs in the treatment of pain following dental surgery.

the duration of treatment is 1 day.

Eligibility criteria:
inclusion criteria: * impaction of a molar tooth requiring removal exclusion criteria: * known allergies to the study drug

Keywords: dental surgery molar removal